Abstract

Objective — determining the therapeutic efficacy of a six-week use of Solivin™ cream among patients with plaque psoriasis and eczema. 
 Materials and methods. 60 patients aged 18 to 60 years were monitored. There were 30 people with plaque psoriasis including 10 men and 20 women, and 30 people — with chronic eczema including 12 men and 18 women.
 Results and discussions. The PASI index decreased from moderate to mild severity in 100 % of patients with psoriasis when using Solivin™ cream (monotherapy), residual effects in the form of erythema were observed in 42 % of patients. The PASI index decreased to mild severity in 100% of patients when using Solivin™ cream in combination with selective phototherapy (SFT 311 nm), and residual erythema was observed in 28 % of patients. The eczema area and severity index (EASI) decreased to moderate severity in 62 % of patients with eczema after using Solivin™ cream (monotherapy) and in 5 % of patients decreased to mild. 33 % of patients had no clinical manifestations. Residual effects expressed as erythema were observed in 24% of patients. The EASI index significantly decreased to mild in 44 % of patients when using Solivin™ cream in combination with SFT (311 nm), and to moderate in 56 % of patients. No side effects were observed. All patients tolerated the treatment well.
 Conclusions. High efficiency of Solivin™ cream for problematic skin was observed. The balanced combination of organic active ingredients allows long-term use of the cream without restrictions on the size of the area and the amount of application of the product. When used both as monotherapy and in combination with SFT, a significant decrease in PASI and EASI indices as well as all indicators of clinical manifestations of chronic skin diseases were revealed.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call